How to adapt to choppy waters in biotech ecosystem
As the US enters a new political era, experts predict that the pharmaceutical and clinical trials industry will have to…
All articles by Akosua Mireku
Akosua Mireku
@AkosuaMireku1
Akosua Mireku is a healthcare reporter for Pharmaceutical Technology. Akosua has a Bsc in medical physiology from the University of Manchester. She is particularly interested in topics in neuroscience, rare diseases, and global health equality
-
-
Psoriasis biosimilars and pricing changes herald treatment paradigm disruptions
As biosimilars continue to arrive on the psoriasis scene, wider measures to influence drug access and emerging treatment choices in…
-
Will the tide turn for the wave of pharma layoffs?
Geopolitical events and economic fluctuations have impacted the pharmaceutical industry, inducing a wave of layoffs that have hit both pharma…
-
US Border Protection warns pharma of risks with incorrect biologic importation
The incorrect transport of biological materials opens the US up to the risk of infectious disease and biological threats, says…
-
UAE’s clinical trials space matures with experience from Covid-19
The clinical research landscape of the United Arab Emirates (UAE) is quickly developing with a regulatory framework coming into place…
-
Social media engagement boosts rare disease outreach
Social media has become an excellent tool for targeting specific patients for clinical trials, says Chris Adams, the CEO at…
-
Pharma companies must adapt to keep pace with AI developments, say experts
As artificial intelligence (AI) permeates clinical trial operations more than ever, workforces will have to adapt to the changing tides,…
-
ImmunoPrecise touts potential of rabbit monoclonal antibodies in oncology
There is rising traction surrounding the development of rabbit monoclonal antibodies for cancer treatment, says Jennifer Bath, CEO at ImmunoPrecise…
-
WuXi debates sale of pharma operations as BIOSECURE Act advances
WuXi Biologics and WuXi AppTec are discussing the potential sale of some of their manufacturing units as the BIOSECURE Act…
-
J&J clinches EC approval for first single-pill PAH combo
The European Commission (EC) has approved Johnson and Johnson’s Yuvanci (macitentan + tadalafil) for the treatment of pulmonary arterial hypertension…